Joshua R.  Lamstein net worth and biography

Joshua Lamstein Biography and Net Worth

Chairman of Scopus BioPharma
Joshua R. Lamstein is our Chairman and a director. Mr. Lamstein is also Vice Chairman of HCFP and Co-Chairman and Co-Managing Partner of HCFP/Capital Partners. HCFP/Capital Partners is a co-founder of Scopus. Mr. Lamstein is also a senior officer and/or director of other portfolio companies of HCFP and a Venture Partner of an approximately $100 million seed-stage venture fund. Mr. Lamstein has worked in venture capital and private equity for over 20 years, including as a Managing Director of GF Capital Private Equity Fund, a $240 million middle market private equity fund, and as a Partner of LMS Capital, a FTSE 250 London Stock Exchange-listed investment trust. Mr. Lamstein initiated the trust’s presence in San Francisco and Silicon Valley. He began his career in private equity at Apollo Advisors, a global alternative investment manager now known as Apollo Global Management, Inc. Prior thereto he was an investment banker in New York and London at Lehman Brothers. 

Mr. Lamstein is also a Senior Advisor to John Snow, Inc. and JSI Research & Training Institute, Inc., a non-profit global public health management consulting and research organization dedicated to improving the health of individuals and communities throughout the world. Mr. Lamstein is also on the Board of Trustees of World Education, Inc., a non-profit organization that provides training and technical assistance in literacy, health and HIV and AIDS education around the world.

Mr. Lamstein received his B.A., with honors, from Colgate University and his M.B.A. from the MIT Sloan School of Management.

What is Joshua R. Lamstein's net worth?

The estimated net worth of Joshua R. Lamstein is at least $58.40 as of February 22nd, 2021. Mr. Lamstein owns 116,797 shares of Scopus BioPharma stock worth more than $58 as of December 5th. This net worth evaluation does not reflect any other investments that Mr. Lamstein may own. Learn More about Joshua R. Lamstein's net worth.

How do I contact Joshua R. Lamstein?

The corporate mailing address for Mr. Lamstein and other Scopus BioPharma executives is , , . Scopus BioPharma can also be reached via phone at 212-479-2513. Learn More on Joshua R. Lamstein's contact information.

Has Joshua R. Lamstein been buying or selling shares of Scopus BioPharma?

Joshua R. Lamstein has not been actively trading shares of Scopus BioPharma over the course of the past ninety days. Most recently, on Thursday, August 26th, Joshua R. Lamstein bought 200 shares of Scopus BioPharma stock. The stock was acquired at an average cost of $4.90 per share, with a total value of $980.00. Learn More on Joshua R. Lamstein's trading history.

Who are Scopus BioPharma's active insiders?

Scopus BioPharma's insider roster includes Ira Greenspan (Chairman), and Joshua Lamstein (Chairman). Learn More on Scopus BioPharma's active insiders.

Joshua R. Lamstein Insider Trading History at Scopus BioPharma

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/26/2021Buy200$4.90$980.00View SEC Filing Icon  
2/22/2021Buy100$9.99$999.00116,797View SEC Filing Icon  
See Full Table

Joshua R. Lamstein Buying and Selling Activity at Scopus BioPharma

This chart shows Joshua R Lamstein's buying and selling at Scopus BioPharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Scopus BioPharma Company Overview

Scopus BioPharma logo
Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses. The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein. Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.
Read More

Today's Range

Now: $0.00
Low: $0.00
High: $0.00

50 Day Range

MA: N/A

2 Week Range

Now: $0.00
Low: $0.00
High: $0.01

Volume

361 shs

Average Volume

2,591 shs

Market Capitalization

$21.04 thousand

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A